Science新发现：肺动脉高压的代谢重编程分子机制
肺动脉高压（PAH）是一种危害严重的心肺疾病，它的特点在于病情会逐渐加重，伴随着明显的症状，并且在病情持续发展下可能会致命。PAH的主要病理特征是肺动脉的结构发生改变，同时血液循环的动力学也出现异常。尽管在过去十年中，PAH的治疗取得了显著进展，但诊断延迟和治疗效果不理想仍然是实现最佳结果的主要障碍。PAH的发病机制复杂，涉及多种病理生理过程，其中炎症和代谢紊乱的作用逐渐受到关注。
Managed Healthcare Executive8 天
Gossamer Study Finds Seralutinib Has Long-Lasting Effects in PAH
Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...
Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...
pulmonologyadvisor2 天
Sotatercept Trial Ends Due to Positive Clinical Program Efficacy Data
The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.
Healio10 天
Winrevair PAH trial stopped due to earlier ‘robust evidence’
The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...
Pharmabiz6 天
Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr ...
Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...
Daily13 天
Merck to stop trial evaluating Winrevair early in pulmonary arterial hypertension
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination ...